Rockwell Medical (NASDAQ:RMTI)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, Stock Target Advisor reports. They presently have a $11.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 411.63% from the company’s previous close.
A number of other equities analysts also recently weighed in on RMTI. Piper Jaffray Companies dropped their target price on Rockwell Medical from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Zacks Investment Research cut shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $9.33.
Shares of RMTI stock opened at $2.15 on Monday. The company has a market capitalization of $145.82 million, a price-to-earnings ratio of -4.57 and a beta of 1.45. Rockwell Medical has a 1-year low of $1.81 and a 1-year high of $6.88. The company has a current ratio of 3.27, a quick ratio of 2.98 and a debt-to-equity ratio of 0.07. The stock’s fifty day simple moving average is $2.23 and its 200-day simple moving average is $2.94.
Large investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Rockwell Medical by 12.4% in the second quarter. BlackRock Inc. now owns 3,659,380 shares of the company’s stock worth $11,015,000 after acquiring an additional 403,252 shares during the last quarter. Vanguard Group Inc. boosted its position in Rockwell Medical by 26.9% during the second quarter. Vanguard Group Inc. now owns 2,853,258 shares of the company’s stock valued at $8,589,000 after purchasing an additional 605,032 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Rockwell Medical in the second quarter valued at about $4,515,000. State Street Corp grew its stake in Rockwell Medical by 7.5% in the third quarter. State Street Corp now owns 1,079,852 shares of the company’s stock valued at $2,980,000 after purchasing an additional 74,883 shares in the last quarter. Finally, Luminus Management LLC purchased a new position in Rockwell Medical in the second quarter valued at about $1,273,000. 21.41% of the stock is owned by institutional investors.
Rockwell Medical Company Profile
Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.